The effect of the combination therapy with sucralfate and famotidine on experimentally induced duodenal ulcers in rats.
The combination of sucralfate (SUC) and famotidine (FAM) at subtherapeutic dose on cysteamine-induced duodenal ulcers (3 x 250 mg/kg) in female rats was studied. Subtherapeutic doses were determined in the preliminary studies. They were 200 mg/kg SUC and 0.2 mg/kg FAM (twice a day). The macroscopic examination was done 24 hours after first application of cysteamine. The effectiveness of SUC and FAM combination in subtherapeutic doses was confirmed by decreased number (from 1.3 to 0.5), length (from 5.5 mm to 1.9 mm), severity of duodenal ulcers (from 3.4 to 1.2) and reduction of ulcerative index by 54.4%.
Zupancic
P
P
Research and Development Division, Novo mesto, Slovenia.
D000818:Animals; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D003543:Cysteamine; D004359:Drug Therapy, Combination; D004381:Duodenal Ulcer / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D015738:Famotidine / Q000627:therapeutic use*; D005260:Female; D051381:Rats; D017208:Rats, Wistar; D013392:Sucralfate / Q000627:therapeutic use*
D000897:Anti-Ulcer Agents; D013392:Sucralfate; D015738:Famotidine; D003543:Cysteamine